{"prompt": "['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 26 of 129', \"Depression Scale; IGA, Investigator's Global Assessment; IgE, immunoglobulin E; IMP, investigational medicinal product;\", 'NIMP, non-investigational medicinal product; NRS, numeric rating scale; POEM, Patient Oriented Eczema Measure;', 'SCORAD, Scoring Atopic Dermatitis; SFU, safety follow-up; TCS, topical corticosteroid.', '5 Introduction and rationale', '5.1 Atopic dermatitis', 'Atopic dermatitis (AD) is a chronic inflammatory skin disease that may affect up to 20% of', 'children and up to 10% of adults. In its severe form, AD is characterised by widespread skin', 'lesions, intractable itch, as well as enhanced susceptibility to bacterial, viral, and fungal skin', 'infections (1-4). AD is associated with a substantial patient burden that typically includes poor', 'quality of life, sleep disturbance, and reductions in work productivity (5).', 'AD is characterised by an activated T-helper-2 (Th2) pathway with increased skin expression', 'of key Th2 cytokines including interleukin (IL)-13 (6,7). The expression of IL-13 is increased', 'in lesional skin compared to non-lesional skin, and the proportion of CD4+ and CD8+ cells', 'expressing IL-13 is upregulated in AD patients compared to individuals without AD (6,8).', 'IL-13 acts on keratinocytes to release C-C motif chemokine 22 (CCL22) and recruit more', 'IL-13 expressing Th2 cells, decrease differentiation, and contribute to decreased barrier', 'function (9). IL-13 also drives immunoglobulin E (IgE) production and contributes to mast', 'cell activation status and, once allergen cross-links IgE on the cell surface, drives histamine', 'release and induces itch (10, 11). Indeed, itch is a key issue in AD, which drives significant', 'mechanical damage to the skin and further facilitates allergen and pathogen entry.', 'These effects together drive and exacerbate the disease phenotype. A review of the available', 'preclinical literature from mouse and human ex vivo models suggests IL-13 as a, if not the,', 'central mediator of the AD skin phenotype. Indeed, there is evidence that blocking the IL-4', 'receptor (which is part of the receptor complex which also binds IL-13) with the monoclonal', 'antibody dupilumab leads to clinical improvement in subjects with AD (12).', '5.2 Experience with investigational medicinal product', 'Tralokinumab is a human recombinant monoclonal antibody of the immunoglobulin G4', '(IgG4) subclass that specifically binds to human IL-13 and blocks interaction with the IL-13', 'receptors (13-15). A compilation of clinical and nonclinical data on tralokinumab including', \"pharmacokinetics (PK) is given in the current version of the Investigator's Brochure.\", 'In total, 13 clinical trials with tralokinumab have been completed to date, with phase 3', 'development ongoing in AD and asthma. Other clinical trials with tralokinumab have been', 'conducted in subjects with ulcerative colitis, idiopathic pulmonary fibrosis, and in healthy', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 27 of 129', 'subjects. Further information on these trials can be found in the current version of the', \"Investigator's Brochure.\", 'In a phase 2b trial (D2213C00001), adults with moderate-to-seven AD on a background of', 'mild to moderate topical corticosteroids (TCS) were treated with 3 different regimens of', 'tralokinumab (45 mg every second week [Q2W], 150 mg Q2W, or 300 mg Q2W) or placebo', 'to evaluate the safety and efficacy over a treatment period of 12 weeks. The primary', 'endpoints were change from baseline in Eczema Area and Severity Index (EASI) at Week 12', \"and the percentage of subjects achieving Investigator's Global Assessment (IGA) response of\", '0 (clear) or 1 (almost clear) at Week 12. Secondary endpoints included change from baseline', 'in EASI and Scoring Atopic Dermatitis (SCORAD) scores, the percentage of subjects', 'achieving at least 50% reduction from baseline in EASI and SCORAD scores (EASI50 and', 'SCORAD50). In the overall intent-to-treat phase 2b population, an improvement in EASI', 'score at Week 12 was seen in the tralokinumab 300 mg Q2W group versus placebo. 26% of', 'subjects achieved an IGA of 0 or 1 in the tralokinumab 300 mg Q2W group versus 12% in the', 'placebo group. The most commonly reported causally related treatment-emergent adverse', 'event (AE) was upper respiratory tract infection (6 subjects [3.9%] in the combined', 'tralokinumab group [45 mg, 150 mg, and 300 mg] and 2 subjects [3.9%] in the placebo', 'group).', 'In total, more than 2,296 subjects have been treated with tralokinumab (cut-off date:', '18-Aug-2016). The safety of all doses studied so far has been with an acceptable benefit-risk', 'profile and no major safety concerns have been identified. Possible risks associated with use', 'of tralokinumab are summarised in Section 5.5.', '5.3 Trial rationale', 'Treatment recommendations for AD include topical therapies, the main being TCS.', 'Unfortunately, TCS and topical calcineurin inhibitors (TCIs) have limited efficacy in patients', 'with moderate-to-severe disease. TCS and non-biologic systemic therapies (e.g. cyclosporine,', 'azathioprine) are all associated with toxicities with long-term use (16-18). The recently', 'approved biological agent dupilumab exhibits an acceptable benefit-risk ratio in clinical trials', 'investigating subjects with moderate-to-severe AD, however there is limited experience with', 'long-term dupilumab use in the post marketing setting.', 'The purpose of this phase 3 trial is to provide evidence of the efficacy and safety of', 'tralokinumab in combination with TCS in the treatment of subjects with moderate-to-severe', 'AD inadequately controlled with topical therapies. Such subjects would be candidates for', 'systemic therapy.', 'TMF-000005673 - Version 4.0']\n\n###\n\n", "completion": "END"}